Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$136.93 USD
-6.25 (-4.37%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $136.88 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ASND 136.93 -6.25(-4.37%)
Will ASND be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ASND
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Other News for ASND
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Ascendis Pharma Gains UK Authorization for YORVIPATH
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
Ascendis Pharma announces MRHA approval of YORVIPATH in Great Britain
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today